Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Silver

Showing results (161-170 of 232) with videos related to

Pageof 24
Sort By:
Medical and Pediatric Oncology|January 1, 1994
Combination trial of subcutaneous recombinant alpha 2 b interferon and oral cyclophosphamide in follicular low-grade non-Hodgkin's lymphomaH Ozer, J R Anderson, B A Peterson, et al.
Cancer|May 19, 2017
The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosisRichard T Silver, Ariella C Barel, Elena Lascu, et al.
Heart Rhythm|August 2, 2019
Additional antitachycardia pacing programming strategies further reduce unnecessary implantable cardioverter-defibrillator shocksBoyoung Joung, Daniel R Lexcen, Chi-Keong Ching, et al.
Journal of the National Cancer Institute|December 15, 1993
Cigarette smoking and risk of acute leukemia: associations with morphology and cytogenetic abnormalities in bone marrowD P Sandler, D L Shore, J R Anderson, et al.
Blood|March 15, 1994
Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemiaA Neubauer, R K Dodge, S L George, et al.
Medical and Pediatric Oncology|January 1, 1979
Combination chemotherapy for non-Hodgkin lymphomas: a ten year follow-up studyD M Hayes, T F Pajak, V Rege, et al.
Leukemia & Lymphoma|December 17, 2002
Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemiaG J Roboz, M A Knovich, R L Bayer, et al.
Blood|September 9, 1999
An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of HematologyR T Silver, S H Woolf, R Hehlmann, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B studyR A Fleming, R L Capizzi, G L Rosner, et al.
Nature Genetics|March 17, 2009
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasmsAmy V Jones, Andrew Chase, Richard T Silver, et al.
Pageof 24

Showing results (161-170 of 232) with videos related to

Sort By:
Pageof 24
Medical and Pediatric Oncology|January 1, 1994
Combination trial of subcutaneous recombinant alpha 2 b interferon and oral cyclophosphamide in follicular low-grade non-Hodgkin's lymphomaH Ozer, J R Anderson, B A Peterson, et al.
Cancer|May 19, 2017
The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosisRichard T Silver, Ariella C Barel, Elena Lascu, et al.
Heart Rhythm|August 2, 2019
Additional antitachycardia pacing programming strategies further reduce unnecessary implantable cardioverter-defibrillator shocksBoyoung Joung, Daniel R Lexcen, Chi-Keong Ching, et al.
Journal of the National Cancer Institute|December 15, 1993
Cigarette smoking and risk of acute leukemia: associations with morphology and cytogenetic abnormalities in bone marrowD P Sandler, D L Shore, J R Anderson, et al.
Blood|March 15, 1994
Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemiaA Neubauer, R K Dodge, S L George, et al.
Medical and Pediatric Oncology|January 1, 1979
Combination chemotherapy for non-Hodgkin lymphomas: a ten year follow-up studyD M Hayes, T F Pajak, V Rege, et al.
Leukemia & Lymphoma|December 17, 2002
Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemiaG J Roboz, M A Knovich, R L Bayer, et al.
Blood|September 9, 1999
An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of HematologyR T Silver, S H Woolf, R Hehlmann, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B studyR A Fleming, R L Capizzi, G L Rosner, et al.
Nature Genetics|March 17, 2009
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasmsAmy V Jones, Andrew Chase, Richard T Silver, et al.
Pageof 24